| Abstract C256: Expanded clinical opportunities for crizotinib from an analysis of over 5,000 cancer patient exomes. S Eddy, M Tomilo, ME Urick, NA Khazanov, P Williams, A Bankhead, ... Molecular Cancer Therapeutics 12 (11_Supplement), C256-C256, 2013 | 2 | 2013 |
| Discovery and characterization of driver MAPK and PI3K pathway mutations in tumors and association with drug response in cell lines. M Tomilo, PD Williams, ET Bowden, SR Gajjala, S Bandla, SF Eddy, ... Cancer Research 73 (8_Supplement), 2897-2897, 2013 | 2 | 2013 |
| A survey of 1,000s of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib DR Emma T. Bowden, Sean F. Eddy, Paul D. Williams, Nickolay A. Khazanov ... https://www.thermofisher.com/content/dam/LifeTech/global/life-sciences …, 2013 | | 2013 |
| Analysis of 3,000 Cancer Exomes to Identify Novel Cancer Drivers and Therapeutic Opportunities DRR Nickolay A. Khazanov, Peter Wyngaard, Paul D. Williams, Armand R ... https://www.genome.gov/multimedia/slides/tcga2/22_khazanov.pdf 1 (1), 1, 2012 | | 2012 |
| Integrated analysis of patient level genetic aberrations in human cancer DR Chris Gates1, Matt Anstett1, Supra Gajjala1, Peter Wyngaard1 http://tools.thermofisher.com/content/sfs/posters/integrated-analysis …, 2011 | | 2011 |
